All In Biotech

NDA 019599 · Legacy

Naftin

Naftifine Hydrochloride · Topical

Novel

Last checked: Nov 20, 2026Latest source record: Apr 30, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Feb 29, 1988

Approved uses

6

Original approval plus efficacy supplements

Registered trials

14

5 Phase 3, 0 recruiting

FAERS reports

334

161 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 10, 2016 Supplement 13 · Efficacy LabelLetterPediatric Medical Review
  • Oct 10, 2014 Supplement 12 · Efficacy LabelLetter
  • Jan 13, 2012 Supplement 11 · Efficacy ReviewLabelLetter
  • Jul 5, 1990 Supplement 2 · Efficacy
  • Apr 5, 1989 Supplement 1 · Efficacy
  • Feb 29, 1988 Original approval · Type 1 - New Molecular Entity
2 products under this application
  • NAFTIN · NAFTIFINE HYDROCHLORIDE 2% · CREAM, TOPICAL · Prescription · TE AB
  • NAFTIN · NAFTIFINE HYDROCHLORIDE 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CREAM, TOPICAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Naftifine" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pruritus33
  • blister27
  • skin exfoliation26
  • hypersensitivity25
  • chronic kidney disease24
  • drug ineffective24
  • rash23
  • erythema21
  • off label use20
  • diarrhoea18
  • pain18
  • renal failure18

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20072
20082
20092
20103
20119
201214
201312
201414
201534
201646
201724
201832
201933
202028
202123
202218
202313
20249
202510
20265

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Naftin (Naftifine HCl)

2024 spending

$776K

Beneficiaries

625

1,409 claims

Per beneficiary

$1,241

$9.79 per unit

View as table
YearSpending
2020$1,948,778
2021$2,237,312
2022$2,875,420
2023$2,362,346
2024$775,716

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Legacy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.